US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Release time：2024-05-22 10:24:55 Source：Culture Compass news portal
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
- Previous：Garcia, Winker go deep as Nats end slide, beat struggling Twins 12
- Next：Tigers starter Olson leaves game against Royals after being struck by line drive
Related articles
- US defender John Brooks to leave German club Hoffenheim
- A meeting of baseball's oldest managers with Washington back in Texas to face Bochy
- Consistent at making cuts, Mark Hubbard now aims to make it pay off at the PGA Championship
- Rays' Tyler Alexander comes within 5 outs of perfect game against Blue Jays
- Rafael Devers sets team record by homering in 6th straight game as Red Sox top Rays 5
- Chinese explorer crosses Taklamakan Desert on foot in 61 days
- China launches new remote sensing satellite
- Brown v. Board: Even with school choice, some Black families find options lacking
- Australia's deputy prime minister pledges support to Solomon Islands during visit to Honiara
- PGA Championship at a glance
- Andretti Global makes key engineering hire in bid to earn a spot in Formula 1
- Dodgers acquire lefty Anthony Banda from Guardians for cash
- China to allow more international flights
- Wanderlust unleashed after restrictions eased
- Caitlin Clark returns for 2nd half against Sun after apparent left leg injury in 1st half
- China makes headway in addressing ship pollution on Yangtze River
- Chinese scientists achieve breakthrough in combating plant cancer
- Angels beat Rangers 9
- Spain withdraws its ambassador to Argentina over comments made by President Milei
- Recovering China outbound, inbound travel boosting global tourism market
Random recommendation
- Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Compass news portal sitemap